Ani Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ANIP Stock | USD 66.52 0.52 0.79% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ANI Pharmaceuticals is 'Strong Buy'. Macroaxis provides ANI Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ANIP positions. The advice algorithm takes into account all of ANI Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting ANI Pharmaceuticals' buy or sell advice are summarized below:
Real Value 75.73 | Target Price 71.67 | Hype Value 66 | Market Value 66.52 | Naive Value 66.05 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell ANI Pharmaceuticals given historical horizon and risk tolerance towards ANI Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for ANI Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
ANI |
Execute ANI Pharmaceuticals Buy or Sell Advice
The ANI recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ANI Pharmaceuticals. Macroaxis does not own or have any residual interests in ANI Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ANI Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
ANI Pharmaceuticals Trading Alerts and Improvement Suggestions
| ANI Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Sage Therapeutics Q1 Earnings Miss, Sales Beat Estimates |
ANI Pharmaceuticals Returns Distribution Density
The distribution of ANI Pharmaceuticals' historical returns is an attempt to chart the uncertainty of ANI Pharmaceuticals' future price movements. The chart of the probability distribution of ANI Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use ANI Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ANI Pharmaceuticals returns is essential to provide solid investment advice for ANI Pharmaceuticals.
| Mean Return | 0.31 | Value At Risk | -1.91 | Potential Upside | 2.58 | Standard Deviation | 2.03 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ANI Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ANI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ANI Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ANI Pharmaceuticals backward and forwards among themselves. ANI Pharmaceuticals' institutional investor refers to the entity that pools money to purchase ANI Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2023-12-31 | 236.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 231.9 K | Macquarie Group Ltd | 2023-12-31 | 230.1 K | Kennedy Capital Management Inc | 2023-12-31 | 229 K | Jpmorgan Chase & Co | 2023-12-31 | 224 K | Thompson, Siegel & Walmsley Llc | 2023-12-31 | 212.9 K | Loomis, Sayles & Company Lp | 2023-12-31 | 180.4 K | Northern Trust Corp | 2023-12-31 | 167.1 K | Nuveen Asset Management, Llc | 2023-12-31 | 159.3 K | Blackrock Inc | 2023-12-31 | 2.5 M | Vanguard Group Inc | 2023-12-31 | 1.3 M |
ANI Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 19.3M | (54.5M) | 92.4M | (52.1M) | 167.9M | 176.3M | |
| Free Cash Flow | 18.1M | (53.1M) | (20.3M) | (47.7M) | 100.4M | 105.5M | |
| Depreciation | 44.6M | 44.6M | 47.3M | 59.7M | 59.8M | 62.8M | |
| Other Non Cash Items | 9.4M | 6.1M | 5.0M | 9.0M | 6.6M | 6.9M | |
| Capital Expenditures | 27.5M | 68.3M | 23.6M | 16.5M | 18.5M | 20.9M | |
| Net Income | 6.1M | (22.5M) | (42.6M) | (47.9M) | 18.8M | 19.7M | |
| End Period Cash Flow | 67.4M | 12.9M | 105.3M | 53.2M | 221.1M | 232.2M | |
| Change To Inventory | (7.7M) | (2.8M) | 3.2M | (23.6M) | (5.8M) | (6.1M) | |
| Dividends Paid | 190K | 5.7M | 618K | 1.6M | (1.6M) | (1.5M) | |
| Change To Netincome | 2.5M | 3.9M | (3.8M) | 321K | 288.9K | 274.5K | |
| Investments | (27.5M) | (68.3M) | (105.5M) | (15.7M) | (16.9M) | (17.7M) | |
| Change Receivables | (7.3M) | (23.7M) | (5.5M) | (36.9M) | (33.2M) | (31.6M) | |
| Net Borrowings | (121.5M) | (534K) | 99.0M | (3M) | (2.7M) | (2.6M) |
ANI Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ANI Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ANI Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ANI stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.26 | |
β | Beta against NYSE Composite | 0.77 | |
σ | Overall volatility | 2.03 | |
Ir | Information ratio | 0.12 |
ANI Pharmaceuticals Volatility Alert
ANI Pharmaceuticals has relatively low volatility with skewness of 3.14 and kurtosis of 17.99. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ANI Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ANI Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ANI Pharmaceuticals Fundamentals Vs Peers
Comparing ANI Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ANI Pharmaceuticals' direct or indirect competition across all of the common fundamentals between ANI Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as ANI Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ANI Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ANI Pharmaceuticals to competition |
| Fundamentals | ANI Pharmaceuticals | Peer Average |
| Return On Equity | 0.0472 | -0.31 |
| Return On Asset | 0.0372 | -0.14 |
| Profit Margin | 0.04 % | (1.27) % |
| Operating Margin | 0.07 % | (5.51) % |
| Current Valuation | 1.41 B | 16.62 B |
| Shares Outstanding | 20.98 M | 571.82 M |
| Shares Owned By Insiders | 11.20 % | 10.09 % |
| Shares Owned By Institutions | 75.96 % | 39.21 % |
| Number Of Shares Shorted | 213.52 K | 4.71 M |
| Price To Earning | 43.35 X | 28.72 X |
| Price To Book | 3.24 X | 9.51 X |
| Price To Sales | 2.88 X | 11.42 X |
| Revenue | 486.82 M | 9.43 B |
| Gross Profit | 177.6 M | 27.38 B |
| EBITDA | 109.32 M | 3.9 B |
| Net Income | 18.78 M | 570.98 M |
| Cash And Equivalents | 63.38 M | 2.7 B |
| Cash Per Share | 3.89 X | 5.01 X |
| Total Debt | 315.33 M | 5.32 B |
| Debt To Equity | 0.85 % | 48.70 % |
| Current Ratio | 3.35 X | 2.16 X |
| Book Value Per Share | 22.64 X | 1.93 K |
| Cash Flow From Operations | 118.96 M | 971.22 M |
| Short Ratio | 1.29 X | 4.00 X |
| Earnings Per Share | 0.85 X | 3.12 X |
| Price To Earnings To Growth | 1.06 X | 4.89 X |
| Target Price | 79.8 | |
| Number Of Employees | 642 | 18.84 K |
| Beta | 0.8 | -0.15 |
| Market Capitalization | 1.4 B | 19.03 B |
| Total Asset | 904.42 M | 29.47 B |
| Retained Earnings | (80.13 M) | 9.33 B |
| Working Capital | 374.34 M | 1.48 B |
Note: Disposition of 13502 shares by Ori Gutwerg of ANI Pharmaceuticals at 62. subject to Rule 16b-3 [view details]
ANI Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ANI . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ANI Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell ANI Pharmaceuticals? Buying financial instruments such as ANI Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 63.6M | 69.3M | 99.8M | 104.8M | Total Assets | 771.6M | 760.1M | 904.4M | 949.6M |
Use Investing Ideas to Build Portfolios
In addition to having ANI Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold ETFs Thematic Idea Now
Gold ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Gold ETFs theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ANI Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.